Epclusa is a fixed-dose combination antiviral medicine containing sofosbuvir 400 mg and velpatasvir 100 mg. It is indicated for the treatment of chronic hepatitis C virus (HCV) infection across all major genotypes (1–6), making it a pan-genotypic treatment option for a wide range of patients.

The two active ingredients work through complementary mechanisms to inhibit essential proteins required for hepatitis C viral replication. Sofosbuvir is an NS5B polymerase inhibitor, while velpatasvir is an NS5A inhibitor. Together, they help prevent the virus from multiplying and allow the body to clear the infection.

Epclusa is administered as an oral tablet taken once daily, with or without food. The standard treatment duration is typically 12 weeks, although treatment plans may vary depending on factors such as liver disease severity, previous HCV treatment history, and whether the medication is used in combination with other therapies.

Clinical studies have demonstrated sustained virologic response (SVR) rates exceeding 95% in many patient populations, making Epclusa one of the leading therapies for chronic hepatitis C. Successful treatment can reduce the risk of liver-related complications, including cirrhosis, liver failure, and hepatocellular carcinoma.

Common side effects may include headache, fatigue, nausea, insomnia, and weakness. Patients with advanced liver disease or those taking certain medications may require additional monitoring and treatment considerations. Healthcare providers should review potential drug interactions before initiating therapy.